$ 208.80
Details
Reacts with the “cytolytic T lymphocyte-associated antigen”, CTLA-4. CTLA-4 is transiently expressed on activated CD28 T cells and binds to CD80 and CD86 present on antigen presenting cells (APC) with high avidity. This interaction appears to deliver a negative regulatory signal to the T cell. There are recent reports that indicate that CTLA-4 is also expressed on B cells when cultured with activated T cells, suggesting a possible role of CTLA-4 in the regulation of B-cell response. Immobilized BNI3.1 enhances T-cell proliferation induced by CD3 and CD28. Recent studies have showed that CD152 can be expressed by regulatory T (Treg) cells. It has been found this antibody can stain the intracellular CD152 on the Treg cells after fixation and permeabilization of cells. Clone BNI3 also cross-reacts with a subset of peripheral blood lymphocytes of baboon, and both rhesus and cynomolgus macaque monkeys, following Concanavalin A (Con A) treatment. The distribution of BNI3 cells following activation is similar to that observed with peripheral blood lymphocytes from normal human donors. This antibody is routinely tested by flow cytometric analysis. Other applications were tested at BD Biosciences Pharmingen during antibody development only or reported in the literature.
